Standard markers such as PD-L1 expression and tumor mutation burden (TMB), which guide checkpoint inhibitor (ICI) use in malignancies like lung cancer and melanoma, have shown limited predictive value in OC [176]. This evidence concerns the gene CD274 and lung carcinoma.